BRUKINSA patients can call the myBeOne Support^™ program to talk to a dedicated nurse: 1-833-234-4363

THE FIRST AND ONLY HEAD-TO-HEAD TRIAL OF BTK INHIBITORS IN WM*

ASPEN (STUDY 302)

BRUKINSA® (zanubrutinib) vs ibrutinib head-to-head

A Phase 3, randomized, open-label, multicenter trial conducted globally across 61 sites comparing BRUKINSA with ibrutinib in 229 patients with WM^1,2

2 COHORTS WERE ANALYZED^1-4

COHORT 1 (N=201)

Patients with MYD88^MUT WM were randomized 1:1 to receive BRUKINSA or ibrutinib

Initial Analysis: 19 months
Long-Term Analysis: 44 months

COHORT 2 (EXPLORATORY; N=28)

Patients with MYD88^WT WM received BRUKINSA

Initial Analysis: 18 months
Long-Term Analysis: 43 months

The primary endpoint of proportion of patients achieving a CR or VGPR in Cohort 1 was assessed by IRC based on standard and modified response criteria from the 6th International Workshop on Waldenström’s Macroglobulinemia (IWWM-6).¹

*Patients were enrolled from the United States, Europe, and Australia/New Zealand.²

BTK=Bruton’s tyrosine kinase; CR=complete response; IRC=independent review committee; MUT=mutated; VGPR=very good partial response; WM=Waldenström’s macroglobulinemia; WT=wild type.

ASPEN (STUDY 302) PATIENT DISPOSITION^1-3ELIGIBLE PATIENTS

• Histological diagnosis of WM

• Meeting ≥1 criterion for treatment initiation

• No prior BTK inhibitors

^†Cohort 2 Rationale: Since major responses have not previously been observed in ibrutinib-treated patients with MYD88^WT, patients found to have MYD88^WT by gene sequencing (n=26) or those with unknown/inconclusive MYD88^WT mutational status (n=2) were assigned to receive BRUKINSA in this separate single-arm exploratory analysis.⁵

BID=twice daily; BTK=Bruton’s tyrosine kinase; MUT=mutated; PD=progressive disease; QD=once daily; R=randomization; R/R=relapsed/refractory; TN=treatment naïve; WM=Waldenström’s macroglobulinemia; WT=wild type.

BASELINE PATIENT CHARACTERISTICS IN A RANGE OF PATIENTSPATIENT CHARACTERISTICS: COHORT 1^2,6

Baseline Patient Characteristics	BRUKINSA (n=102)	Ibrutinib (n=99)
Median age	70 years (range: 45-87)	70 years (range: 38-90)
Age >75 years	33%	22%
Caucasian	86%	96%
Median time since diagnosis	4.4 years	4.9 years
Median prior regimens	1 (range: 0-8)	1 (range: 0-6)
Treatment naïve	19%	18%
Median lgM g/L	31.8 (range: 5.8-87)	34.2 (range: 2.4-108)
ECOG
0/1	94%	93%
Prognostic category
Low	17%	13%
Intermediate	37%	42%
High	46%	44%
Extramedullary disease	79%	74%
Prior ASCT	2.9%	1.0%
Genotype by NGS
MYD88^L265P/CXCR4^WT	89%	91%
MYD88^L265P/CXCR4^WHIM	11%	8%

COMORBIDITIES: COHORT 1²

Baseline Patient Characteristics	BRUKINSA (n=102)	Ibrutinib (n=99)
Preexisting conditions
Atrial fibrillation/flutter	10%	8%
Hypertension	38%	43%

ASCT=autologous stem cell transplant; ECOG=Eastern Cooperative Oncology Group; NGS=next-generation sequencing; WHIM=WHIM syndrome-like somatic mutation; WT=wild type.

POWERFUL AND
SUSTAINED RESPONSES

EFFICACY

ESTABLISHED
SAFETY PROFILE

SAFETY

PERSONALIZED
PATIENT SUPPORT

VISIT myBeOneSupport.com

IMPORTANT SAFETY INFORMATION

What should I tell my healthcare provider before taking BRUKINSA?

Before taking BRUKINSA, tell your healthcare provider about all of your medical conditions, including if you:

have bleeding problems.
have had recent surgery or plan to have surgery. Your healthcare provider may stop BRUKINSA for any planned medical, surgical, or dental procedure.
have an infection.
have or had heart rhythm problems.
have high blood pressure.
have liver problems, including a history of hepatitis B virus (HBV) infection.
are pregnant or plan to become pregnant. BRUKINSA can harm your unborn baby. If you are able to become pregnant, your healthcare provider may do a pregnancy test before starting treatment with BRUKINSA.

Females should avoid getting pregnant during treatment and for 1 week after the last dose of BRUKINSA. You should use effective birth control (contraception) during treatment and for 1 week after the last dose of BRUKINSA.
Males should avoid getting female partners pregnant during treatment and for 1 week after the last dose of BRUKINSA. You should use effective birth control (contraception) during treatment and for 1 week after the last dose of BRUKINSA.

are breastfeeding or plan to breastfeed. It is not known if BRUKINSA passes into your breast milk. Do not breastfeed during treatment with BRUKINSA and for 2 weeks after the last dose of BRUKINSA.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Taking BRUKINSA with certain other medications may affect how BRUKINSA works and can cause side effects.

What are the possible side effects of BRUKINSA?

BRUKINSA may cause serious side effects, including:

Bleeding problems (hemorrhage). Bleeding problems are common with BRUKINSA, and can be serious and may lead to death. Your risk of bleeding may increase if you are also taking a blood thinner medicine. Tell your healthcare provider if you have any signs or symptoms of bleeding, including:

blood in your stools or black stools (looks like tar)
pink or brown urine
unexpected bleeding, or bleeding that is severe or you cannot control
vomit blood or vomit that looks like coffee grounds
cough up blood or blood clots
increased bruising
dizziness
weakness
confusion
change in speech
headache that lasts a long time

Infections that can be serious and may lead to death. Tell your healthcare provider right away if you have fever, chills, or flu-like symptoms.
Decrease in blood cell counts (white blood cells, platelets, and red blood cells). Your healthcare provider should do blood tests during treatment with BRUKINSA to check your blood counts.
Second primary cancers. New cancers have happened in people during treatment with BRUKINSA, including cancers of the skin or other organs. Your healthcare provider will check you for other cancers during treatment with BRUKINSA. Use sun protection when you are outside in sunlight.
Heart rhythm problems (atrial fibrillation, atrial flutter, and ventricular arrhythmias) that can be serious and may lead to death. Tell your healthcare provider if you have any of the following signs or symptoms:

your heartbeat is fast or irregular
feel lightheaded or dizzy
pass out (faint)
shortness of breath
chest discomfort

Liver problems. Liver problems, which may be severe or life-threatening, or lead to death, can happen in people treated with BRUKINSA. Your healthcare provider will do blood tests to check your liver before and during treatment with BRUKINSA. Tell your healthcare provider or get medical help right away if you have any signs of liver problems, including stomach pain or discomfort, dark-colored urine, or yellow skin and eyes.

The most common side effects of BRUKINSA include:

decreased white blood cell count
decreased platelet count
upper respiratory tract infection
bleeding
muscle, bone, or joint pain

These are not all the possible side effects of BRUKINSA. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

What is BRUKINSA?

BRUKINSA is a prescription medicine used to treat adults with:

Chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
Waldenström’s macroglobulinemia (WM).
Mantle cell lymphoma (MCL) who have received at least one prior treatment for their cancer.
Marginal zone lymphoma (MZL) when the disease has come back or did not respond to treatment and who have received at least one certain type of treatment.
Follicular lymphoma (FL), in combination with the medicine obinutuzumab, when the disease has come back or did not respond to treatment and who have received at least two prior treatments.

It is not known if BRUKINSA is safe and effective in children.

Please see full Prescribing Information including Patient Information.

References: 1. BRUKINSA. Package insert. BeiGene USA, Inc.; 2025. 2. Tam CS, Opat S, D’Sa S, et al. A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN study. Blood. 2020;136(18):2038-2050. 3. Dimopoulos M, Sanz RG, Lee HP, et al. Zanubrutinib for the treatment of MYD88 wild-type Waldenström macroglobulinemia: a substudy of the phase 3 ASPEN trial. Blood Adv. 2020;4(23):6009-6018. 4. Tam CS, Garcia-Sanz R, Opat S, et al. ASPEN: long-term follow-up results of a phase 3 randomized trial of zanubrutinib versus ibrutinib in patients with Waldenström macroglobulinemia. Poster presented at: American Society of Clinical Oncology (ASCO) 2022 Annual Meeting; June 3-7, 2022. Abstract 7521. 5. Treon SP, Tripsas CK, Meid K, et al. Ibrutinib in previously treated Waldenström’s macroglobulinemia. N Engl J Med. 2015;372(15):1430-1440. 6. Data on ﬁle. BeiGene USA, Inc.

Want to learn about a different indication?

CLL/SLL MCL MZL FL

BRUKINSA for WM The BRUKINSA Difference

Study Design Efficacy Safety